Table 2.

Summary of the characteristics of the included clinical trials on Milrinone or Dobutamine in the management of cardiogenic shock [12,[34], [35], [36]].

Authors	Objective	Methods	Results	Conclusions
Mathew et al. [12]	To evaluate the efficacy of Milrinone vs. Dobutamine in patients with cardiogenic shock	Randomized double-blind clinical trial involving 192 participants (96 in each group)	No significant differences were found with respect to in-hospital mortality (RR 0.85; 95% CI, 0.60–1.21), cardiac resuscitation (RR 0.78; 95% CI, 0.29–2.07), receipt of mechanical circulatory support (RR 0.78; 95% CI, 0.36–1.71) and initiation of renal replacement therapy (RR 1.39; 95% CI, 0.73–2.67), in both groups.	In patients with cardiogenic shock, there are no significant differences between the use of Milrinone vs. Dobutamine, with respect to primary outcomes (mortality and need for specialized approach) and secondary outcomes
Parlow et al. [34]	To evaluate the impact of mean arterial pressure in patients with cardiogenic shock under treatment with Milrinone or Dobutamine	Post hoc analysis of the CAPITAL DOREMI clinical trial. Where two intervention arms were established (mean arterial pressure ≥70 mmHg per 36 h vs. mean arterial pressure ≤70 mmHg per 36 h)	Primary outcomes (all-cause mortality, resuscitated cardiac arrest, need for cardiac transplantation, stroke or initiation of renal therapy) were more frequent in the group with low mean arterial pressure (67.6% vs. 42.2%).	In patients with cardiogenic shock under treatment with Milrinone or Dobutamine, low mean arterial pressure values are associated with worse outcomes
Di Santo et al. [35]	To evaluate clinical and hemodynamic outcomes in the use of beta-blockers in patients with cardiogenic shock under treatment with Dobutamine or Milrinone	Subgroup analysis of the DOREMI clinical trial. 192 patients were included, and primary outcomes (all-cause mortality, resuscitated cardiac arrest, need for cardiac transplantation, stroke or initiation of renal therapy, among others) were evaluated	93 patients received beta-blockers. Primary outcomes occurred in 51% of the intervention group vs. 53% in the control group (RR 0.96; 95% CI 0.73–1.27; p = 0.78). Lower mortality was observed in the intervention group (RR 0.41; 95% CI 0.18–0.95; p = 0.03)	The use of beta-blockers 24 h prior to the development of cardiogenic shock with Dobutamine or Milrinone management, did not influence clinical and hemodynamic outcomes. However, their use showed a slight reduction in mortality
Jung et al. [36]	To evaluate the implications of acute myocardial infarction in patients with cardiogenic shock under treatment with Milrinone and Dobutamine	Subgroup analysis of the DOREMI clinical trial. 192 patients were included (65 with acute myocardial infarction vs. 127 without infarction).	Higher all-cause mortality, need for mechanical circulatory support and initiation of renal therapy were observed in the infarction group (HR 2.21; 95% CI, 1.47–3.30; p = 0.0001). Inotropic was found to be associated, although not significantly, with final outcome.	Acute myocardial infarction is significantly associated with worse clinical outcomes, mainly with initiation of mechanical circulatory support and mortality